| | | | | |
Preheader will be populated with an approved preheaders in: LMA-US-RET-092019-00006 | | | | View for web and mobile | | | | This email is intended for US healthcare providers only. | | |
| | | | Focusing on RET in cancer: | | | | | | RET fusions can drive tumor growth in NSCLC1,2 | | | |
| | | | | In NSCLC, several different genomic alterations, including EGFR, ALK, ROS1, NTRK, and BRAF, have been shown to promote cancer growth and define distinct molecular subgroups.1,2 RET gene fusions can also act as a primary oncogenic driver in NSCLC.1,2 | | | | | | | | | | |  | | | | | | RET fusions are found in approximately 2% of NSCLC.1,3,4 | | | |
| | | | | With the emergence of many different biomarkers in NSCLC requiring molecular testing, it’s important to consider transitioning from single biomarker testing to tissue-efficient next-generation sequencing (NGS) methods.5 | | | | | | If an NGS test is not accessible, talk to a pathologist about alternative molecular testing options, including FISH and reverse-transcription PCR.6 | | | |
| | | | | | | | ALK=anaplastic lymphoma kinase; BRAF=v-raf murine sarcoma viral oncogene homolog B; EGFR=epidermal growth factor receptor; FISH=fluorescence in situ hybridization; NTRK=neurotrophic tropomyosin receptor kinase; PCR=polymerase chain reaction; RET=rearranged during transfection; ROS1=c-ros oncogene 1. | | | | | | References: 1. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):150. 2. Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4(2):156-164. 3. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-384. 4. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381. 5. Nagahashi M, Shimada Y, Ichikawa H, et al. Next generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci. 2019;110(1):6-15. 6. Takeuchi K. Discovery stories of RET fusions in lung cancer: a mini-review. Front Physiol. 2019;10:216. doi:10.3389/fphys.2019.00216. | | | | | | Copyright © 2019 Loxo Oncology, Inc, 2019, All Rights Reserved. LMA-US-RET-092019-00005 | | | | | |  | | | |
|
|
|
